Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases
- PMID: 32652113
- DOI: 10.1016/j.annonc.2020.06.021
Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases
Conflict of interest statement
Disclosures Research funding (to institution) from Genentech, Merck, Pfizer, Seattle Genetics. Advisory board/consulting (NUL): Seattle Genetics, Puma, Daiichi Sankyo, AstraZeneca.
Comment on
-
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆.Ann Oncol. 2020 Oct;31(10):1350-1358. doi: 10.1016/j.annonc.2020.06.020. Epub 2020 Jul 5. Ann Oncol. 2020. PMID: 32634611 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical